SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesothelioma

N Crawford1, J Stasik1, C Holohan1, J Majkut1, M McGrath1, PG Johnston1, G Chessari2, GA Ward2, DJ Waugh1, DA Fennell3 and DB Longley*1,1

Malignant pleural mesothelioma (MPM) is a highly pro-inflammatory malignancy that is rapidly fatal and increasing in incidence. Cytokine signaling within the pro-inflammatory tumor microenvironment makes a critical contribution to the development of MPM and its resistance to conventional chemotherapy approaches. SMAC mimetic compounds (SMCs) are a promising class of anticancer drug that are dependent on tumor necrosis factor alpha (TNFα) signaling for their activity. As circulating TNFα expression is significantly elevated in MPM patients, we examined the sensitivity of MPM cell line models to SMCs. Surprisingly, all MPM cell lines assessed were highly resistant to SMCs either alone or when incubated in the presence of clinically relevant levels of TNFα. Further analyses revealed that MPM cells were sensitized to SMC-induced apoptosis by siRNA-mediated downregulation of the caspase 8 inhibitor FLIP, an antiapoptotic protein overexpressed in several cancer types including MPM. We have previously reported that FLIP expression is potently downregulated in MPM cells in response to the histone deacetylase inhibitor (HDACi) Vorinostat (SAHA). In this study, we demonstrate that SAHA sensitizes MPM cells to SMCs in a manner dependent on its ability to downregulate FLIP. Although treatment with SMC in the presence of TNFα promoted interaction between caspase 8 and the necrosis-promoting RIPK1, the cell death induced by combined treatment with SAHA and SMC was apoptotic and mediated by caspase 8. These results indicate that FLIP is a major inhibitor of SMC-mediated apoptosis in MPM, but that this inhibition can be overcome by the HDACi SAHA.

Cell Death and Disease (2013) 4, e733; doi:10.1038/cddis.2013.258; published online 18 July 2013

Subject Category: Cancer

The defining features of cIAP1, cIAP2 and XIAP are their three baculovirus IAP repeat (BIR) domains and their RING zinc-finger domains.11–12 The BIR domains are important for mediating protein–protein interactions, and the RING domain possesses E3 ubiquitin ligase activity. XIAP is the only IAP that directly inhibits caspases: XIAP binds to caspases 3 and 7 via the region between its BIR1 and BIR2 domains and via the BIR2 domain itself, thereby directly inhibiting caspase activity. In addition, the BIR3 domain of XIAP can bind to and prevent homodimerization of caspase 9, thereby preventing its activation. There is also evidence that XIAP may target caspases for ubiquitination and degradation by the proteasome via its RING domain.13–16

The roles of cIAP1 and cIAP2 are more complex and involve regulation of signaling via TNF receptor 1 (TNFR1).16,17 Following binding of the pro-inflammatory cytokine TNFα, TNFR1 recruits an adapter protein TRADD (TNFRF-associated death domain) and receptor-interacting protein kinase 1 (RIPK1). TRADD recruits TRAF2 (TNFRF-associated factor 2), and cIAP1 and cIAP2 to form a large membrane complex. At this complex (termed complex II), cIAP1 and cIAP2 act as E3 ubiquitin ligases adding lysine 63 (K63)-

1Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Science, Queen’s University Belfast, Belfast, Northern Ireland, UK; 2Astex Pharmaceuticals, 436 Cambridge Science Park, Cambridge, UK and 3University of Leicester & Leicester University Hospitals, Leicester, UK

Keywords: mesothelioma; HDAC inhibitors; SAHA/Vorinostat; FLIP: SMAC mimetics.

Abbreviations: MPM, malignant pleural mesothelioma; SMAC, second mitochondrial derived activator of caspases; SMC, SMAC mimetic compound; TNFα, tumor necrosis factor alpha; SAHA, Vorinostat; RIPK1, receptor-interacting protein kinase; IAP, inhibitor of apoptosis; TNFR, tumor necrosis factor receptor; FLIP, CASP8 and FADD-like apoptosis regulator; FADD, Fas-associated via death domain; HDACi, histone deacetylase inhibitor; BIR, baculovirus IAP repeat; DED, death effector domain; TRADD, TNFR-associated death domain; TRAF2, TNFR-associated factor 2; NFκB, nuclear factor kappa B

Received 28.3.13; revised 06.6.13; accepted 07.6.13; Edited by A Stephanou
linked polyubiquitin chains to RIPK1. Polyubiquitinated RIPK1 then serves as a docking site for the downstream kinases that activate the canonical nuclear factor-κB (NF-κB, RelA/p50) signaling pathway. In the absence of cIAP1/2, RIPK1 is not polyubiquitinated and forms a second complex (complex IIb), which recruits Fas-associated via death domain (FADD), caspase 8 and FLIP. FLIP is an antiapoptotic caspase 8 paralog, Complex IIb, which is composed of TRADD, FADD, caspase 8 and FLIP. Thus, by ubiquitinating RIPK1, cIAP1 and cIAP2 act as positive regulators of the generally antiapoptotic, pro-inflammatory canonical NF-κB signaling pathway and at the same time inhibit caspase 8 activation in response to ligation of TNFR1. Complex I can dissociate to form Complex IIa, a death inducing complex similar to Complex IIb, which is composed of TRADD, FADD, caspase 8 and FLIP. FLIP is an antiapoptotic caspase 8 paralog, which prevents Complexes IIa and IIb from initiating apoptosis. Moreover, FLIP is the product of an NFκB target gene (CFLAR) and therefore is upregulated following TNFR1 ligation. FLIP is mainly expressed as two splice forms: a long form FLIP(L) and a short form FLIP(S). FLIP inhibits apoptosis through binding to FADD and blocking caspase 8 activation in Complex IIa and IIb. Under certain conditions Complex II can induce cell death through an non-apoptotic, programmed necrosis pathway, which is dependent on RIPK1 and 3.

IAPs are recognized as attractive targets for anticancer therapeutics. Cellular IAP 1 (cIAP1), cIAP2 and X-linked IAP (XIAP) are the cellular targets for SMAC mimetic compounds (SMCs), which mimic the functions of the endogenous IAP antagonist SMAC. Second mitochondrial derived activator of caspases (SMAC) is released from the mitochondria by various stimuli and promotes apoptosis through its ability to antagonize IAP-mediated caspase inhibition. SMCs bind to BIR2 and three domains of XIAP and neutralize its inhibition of caspases 3 and 7. SMCs also bind cIAP1 and cIAP2, resulting in a conformational change that leads to RING dimerization and activation of their E3 ligase activity, resulting in their rapid autoubiquitination and degradation. As ligation of TNFR1 by TNFα in the absence of cIAP1 and cIAP2 rapidly leads to formation of the cell death inducing complex IIb, we hypothesized that the high levels of TNFα associated with mesothelioma would make this disease particularly vulnerable to SMCs. We therefore investigated whether SMC-mediated inhibition of IAPs could use extracellular TNFα to drive apoptosis in mesothelioma.

**Results**

**Effects of AT-IAP on cIAP and FLIP expression in MPM.** To model the impact of SMCs in mesothelioma, we selected four MPM cell line models with different levels of cIAP1, cIAP2 and XIAP expression (Figure 1a). These cell line models also differed in their expression levels of FLIP(L), FLIP(S) and FADD, although expression of RIPK1 and procaspase eight were similar across the panel. Of note,
TNFα was undetectable in the culture medium of these cell lines under basal conditions and following treatment with SMCs (data not shown). The MPM cell lines also expressed TNFR1 on the cell surface to varying levels (Figure 1b). In this study, we used a novel SMC (AT-IAP) from Astex Pharmaceuticals that is a monovalent inhibitor with nanomolar affinity for the BIR3 domain of both XIAP and cIAP1 (Supplementary Figure 1A). AT-IAP also induces apoptosis in the breast cancer cell lines EVSA-T and MDA-MB-231, which are sensitive to cIAP1 inhibition (Supplementary Figure 1B). Expression levels of FLIP are lower in MDA-MB-231 cells compared with a panel of mesothelioma cells (Supplementary Figure 1C).

Consistent with the expected pharmacodynamic effects of a SMC, treatment of MPM cells with AT-IAP downregulated cIAP1 and cIAP2 expression within 1 h of treatment (Figure 1c and Supplementary Figure 2A). Moreover, cIAP2 mRNA (Figure 1d and Supplementary Figure 2B) and protein expression (Figure 1c and Supplementary Figure 2A) recovered rapidly following treatment with AT-IAP, consistent with the expected activation of the non-canonical NIK-dependent NFκB pathway following treatment with a SMC. Although cIAP1 mRNA increased in response to AT-IAP (Figure 1d and Supplementary Figure 2B), its protein expression remained suppressed (Figure 1c and Supplementary Figure 2A). Increased mRNA expression of the NFκB target gene encoding TNFα was also observed (Figure 1d and Supplementary Figure 2B), as was increased mRNA (Figure 1d and Supplementary Figure 2B) and protein expression (Figure 1c and Supplementary Figure 2A) of the caspase 8 inhibitor and NFκB target gene, FLIP. Furthermore, treatment with concentrations of AT-IAP as low as 10 nM induced cIAP1 downregulation, demonstrating the high on-target potency of this agent (Figure 1e and Supplementary Figure 2C).

**MPM cell lines are insensitive to AT-IAP.** To assess the sensitivity of MPM cells to AT-IAP, we conducted cell viability assays in the presence and absence of cotreatment with a physiologically relevant concentration of TNFα (10 ng/ml) in order to mimic the pro-inflammatory micro-environment of mesothelioma. Surprisingly, none of the MPM cell lines were sensitive to AT-IAP at concentrations up to 10 μM, either alone, or in cells cocultured with TNFα (Figure 2a). Similar results were obtained with several other SMCs (data not shown). To determine whether high expression of IAPs was responsible for resistance to AT-IAP, we used siRNA to individually downregulate cIAP1, cIAP2 and XIAP (Figure 2a).

![Cell viability assays](image-url)

Figure 2 (a) Cell viability assays in (i) REN, (ii) MM98, (iii) H28 and (iv) JU77 cell lines following treatment with 100 μM, 10 μM and 1 μM AT-IAP either alone or in combination with 10 ng/ml TNFα for 72 h. (b) Cell viability assays in (i) REN, (ii) MM98, (iii) H28 and (iv) JU77 cells transfected with 10 nM SCR, XIAP (XIAPsi), cIAP1 (cIAP1si) or cIAP2 (cIAP2si) for 24 h before treatment with 10 μM AT-IAP wither alone or in combination with 10 ng/ml for a further 48 h (knockdown of target proteins by the individual siRNAs is shown in Supplementary Figure 3A). Experimental results were compared using a two-tailed Student’s t-test. *P < 0.05 and **P < 0.01. Experiments were carried out in triplicate.
In Ren cells cocultured with TNFα, downregulation of cIAP1 and to a lesser extent XIAP and cIAP2 moderately increased sensitivity to AT-IAP (Figure 2b); however, none of the other cell lines was sensitized to AT-IAP following siRNA-mediated IAP depletion, suggesting that high IAP expression is not responsible for resistance in these models.

**FLIP regulates sensitivity to AT-IAP in MPM.** SMCs are known to promote formation of TNFR complex IIa and b and the ripoptosome, all of which are potentially activating platforms for the initiator caspase, procaspase 8. However, dimerization of procaspase 8 (a prerequisite for its activation) at these complexes can be inhibited by FLIP. Indeed, we found that caspase 8 and FLIP interacted in MPM cells following treatment with AT-IAP and TNFα and moreover, FLIP(L) was recovered in its p43-form indicative of its dimerization with and processing by procaspase 8 at TNFR complex IIb (Figure 3a). Of note, RIPK1 also interacted with caspase 8 in AT-IAP/TNFα-treated cells (Figure 3a), but not in cells treated with AT-IAP alone or TNFα alone (Supplementary Figure 4A). Further evidence that this caspase 8/RIPK1 complex is complex IIb was obtained in cells in which the critical adapter protein for this complex FADD was silenced, as FADD downregulation abrogated the interaction between caspase 8 and RIPK1 (Supplementary Figure 4B).

To assess whether FLIP expression in MPM cells is responsible for their resistance to SMCs, we downregulated FLIP expression with siRNA and assessed sensitivity to AT-IAP in the presence and absence of TNFα. A FLIP(L) and FLIP(S) dual-targeted siRNA and splice form-specific siRNAs were used (Figure 3b and Supplementary Figure 3B). The cell lines exhibited different levels of sensitivity to FLIP depletion alone as assessed in cell viability experiments, with Ren and H28 cells sensitive to loss of either splice form, MM98 cells sensitive to simultaneous downregulation of both splice forms and Ju77 insensitive to FLIP depletion alone (Figure 3c). In Ren cells cocultured with TNFα, downregulation of either splice form increased cell death in response to AT-IAP.

![Figure 3](image)
although the most potent effects were observed when both splice forms were simultaneously downregulated (Figure 3c(i)). Similar results were obtained in MM98 cells (Figure 3c(ii)). In H28 and JU77 MPM cells, downregulation of FLIP(S) failed to enhance AT-IAP/TNFα-induced cell death, whereas FLIP(L) downregulation significantly enhanced cell death (Figure 3c(iii) and iv). These differences between the cell lines may be related to their relative levels of FLIP(L) and FLIP(S) expression, as well as different levels of expression of other components of the TNFR1 signaling pathway (Figure 1a).

Consistent with these findings, siRNA-mediated downregulation of either FLIP(L) or FLIP(S) enhanced caspase 3 processing and PARP cleavage in AT-IAP/TNFα-treated MPM Ren cells, although maximal levels of PARP cleavage were observed when both splice forms were simultaneously downregulated (Figure 4a). Also of note, treatment with TNFα alone induced PARP cleavage when either FLIP(S) or FLIP(L) were silenced and partially when both splice forms were silenced, consistent with FLIP acting as an inhibitor of TNFR1 complex IIb-induced apoptosis. Somewhat surprisingly, downregulating FLIP did not significantly enhance apoptosis induced by AT-IAP alone (Figures 3c and 4a), suggesting that this combination treatment is not sufficient to drive complex Iib formation. Indeed, we found that FLIP silencing did not promote formation of complex Iib formation either in response to SMC or TNFα treatment (Supplementary Figure 4C). FLIP(L) but not FLIP(S) silencing significantly enhanced apoptosis in Ju77 MPM cells as assessed by flow cytometry, with maximal levels of apoptosis induced when both splice forms were downregulated (Figure 4b). AT-IAP in combination with TNFα in Ren, MM98, Ju77 and H28 cells efficiently activated caspase 8 (Supplementary Figure 5A) and caspase 3/7 (Supplementary Figure 5B) following FLIP silencing (Supplementary Figure 5C).

To further prove that it is FLIP’s recruitment to complex Iib that modulates sensitivity to AT-IAP/TNFα, we utilized a FLIP mutant (F114A) that cannot interact with the critical adapter protein in the complex, FADD\[^{12}\] (Figure 4c). When endogenous FLIP(L) and FLIP(S) proteins were depleted with a 5’-UTR-targeting siRNA (Supplementary Figure 4D), an exogenously expressed wild-type FLIP(S) protein was able to completely rescue the cell death induced by AT-IAP/TNFα treatment, however, the exogenously expressed F114A

![Figure 4](image-url)
FLIP(S) mutant failed to rescue the cell death phenotype (Figure 4d), indicating that FLIP(S) must be able to interact with FADD to inhibit cell death induced by AT-IAP/TNFα.

Interaction between cisplatin and AT-IAP. Cisplatin is one of the standard-of-care chemotherapeutic drugs used to treat mesothelioma and has been previously shown to downregulate FLIP(L) and FLIP(S) expression in several cancers. Treatment of MPM cell lines with cisplatin resulted in significant (>4-fold) downregulation of FLIP(S) in Ren and MM98 cell lines after treatment with 5 μM drug for 48 h, whereas a more modest (~2-fold) downregulation of FLIP(S) was observed in Ju77 and H28 cells and only after treatment with 10 μM cisplatin (Figure 5a). Overall however, the effects of cisplatin treatment on FLIP(L) expression were modest, with significant (>2-fold) downregulation only observed in response to 10 μM cisplatin in Ren cells. Notably, in the two cell lines in which FLIP expression was most downregulated in response to cisplatin, Ren and MM98, significant synergy was observed between cisplatin and AT-IAP in the presence of cotreatment with TNFα (Figure 5b). In H28 and Ju77 cells, the interaction of cisplatin with AT-IAP was less effective at reducing cell viability, with a greater-than-additive effect only observed when cells were treated with 10 μM cisplatin. Thus, increased sensitivity to AT-IAP and TNFα in these mesothelioma models correlated with extent of FLIP downregulation in response to cisplatin (Figures 5a and b). However, these results demonstrate that although cisplatin can induce downregulation of FLIP(S) in some MPM cell lines, it has little effect on FLIP(L) expression.

The HDAC inhibitor SAHA downregulates FLIP and sensitizes MPM cells to AT-IAP. We recently reported that HDAC inhibitors such as SAHA downregulate FLIP(S) and FLIP(L) expression in colorectal cancer and MPM cells in a proteasome-dependent manner. Thus, we assessed whether SAHA could sensitize MPM cells to SMC treatment. SAHA treatment triggered downregulation of both FLIP(L) and FLIP(S) in Ren, MM98 and H28 cells, but not Ju77 cells (Figure 6a). Notably, in those cell lines in which SAHA treatment caused downregulation of FLIP, apoptosis induced by AT-IAP/TNFα was significantly enhanced as assessed by PARP cleavage (Figure 6a), cell viability assays (Figure 6b and Supplementary Figure 6) and caspase 3/7 activity assays (Figure 6c). In contrast, no enhancement of cell death was observed in Ju77 cells in which FLIP was not downregulated in response to SAHA (Figures 6a and c and Supplementary Figure 6). It was also apparent that SAHA treatment enhanced sensitivity to TNFα alone much more than to AT-IAP alone (Figure 6b), which is similar to the results obtained following FLIP silencing described in supplementary material.

![Figure 5](a) Western blot analysis of FLIP(L) and FLIP(S) expression following the treatment of Ren, MM98, H28 and Ju77 cells for 48 h with 1.5 and 10 μM cisplatin. (b) Cell viability assays in (i) Ren, (ii) MM98, (iii) H28 and (iv) Ju77 cells cotreated with 10 μM AT-IAP, 10 ng/ml TNFα or a combination of AT-IAP and TNFα and 1, 5 or 10 μM cisplatin for 48 h.
SAHA overcomes FLIP-mediated inhibition of SMCs
N Crawford et al

above. SAHA also enhanced sensitivity of MPM cells to concentrations of AT-IAP as low as 10 nM and in cells cotreated with concentrations of TNFα as low as 0.1 ng/ml (Figure 6d).

As HDAC inhibitors have multiple effects in cells, we demonstrated that the effects of SAHA on apoptosis induced by AT-IAP/TNFα was due to FLIP downregulation using Ren MPM cell lines overexpressing FLIP(L) and FLIP(S) (Figure 7a). We have previously shown that SAHA is unable to downregulate endogenous FLIP expression in either of these two cell line models. Consistent with FLIP downregulation being necessary for SAHA treatment to promote AT-IAP/TNFα-induced cell death, overexpression of either FLIP(S) or FLIP(L) blocked the effects of SAHA and AT-IAP/TNFα cotreatment on cell death (Figure 7b). To directly prove that combined treatment with SAHA and AT-IAP/TNFα results in apoptosis induction rather than necrosis, we cotreated cells with the pan-caspase inhibitor z-VAD-fmk and the necrosis inhibitor Nec-1. z-VAD-fmk, but not Nec-1, blocked the cytotoxic effects of SAHA and AT-IAP/TNFα cotreatment indicating that the cell death induced is indeed apoptotic (Figure 7c). We further defined the mode of apoptosis induced by SAHA and AT-IAP/TNFα cotreatment to be caspase eight-dependent using siRNA to downregulate procaspase eight levels before treatment. In cells in which procaspase 8 was depleted, the apoptosis induced by SAHA and AT-IAP/TNFα cotreatment was completely abrogated (Figure 7d), indicating that the mechanism of cell death is caspase eight-dependent, consistent with a FLIP-dependent mechanism (Figure 7b). In further support of this mechanism, caspase 8 processing to its p43- and p18-forms was detected in control siRNA transfected, SAHA and AT-IAP/TNFα cotreated cells (Figure 7d, Western blot, lane 3).

Discussion
An inflammatory microenvironment makes a major contribution to cancer progression and drug resistance by promoting tumor cell survival. Chronic inflammation associated with asbestos exposure is strongly linked with initiation and progression of MPM, and a number of studies have established important roles for pro-inflammatory cytokines in MPM tumorigenesis. Circulating TNFα expression is significantly elevated in MPM patients and surgical debulking significantly reduces the levels of circulating TNFα in patients. This is consistent with a substantial TNFα-rich inflammatory cell component associated with MPM. In this study, we examined the activity of a novel SMC in preclinical models of MPM to provide evidence for their clinical evaluation in this disease. In particular, we focused on the impact of TNFα on sensitivity to SMCs as we hypothesized that SMCs could convert this pro-inflammatory cytokine that is present in the mesothelioma microenvironment into a potent apoptosis inducing cytokine by downregulating cIAP1 and 2 and, thereby promoting breakdown of the pro-survival TNFR1 Complex I and formation of the pro-apoptotic Complex II. Thus, the central tenet of our approach was that inhibition of IAP function would divert microenvironment-derived, pro-inflammatory signaling from activating pro-tumorigenic NFκB-driven responses towards apoptosis-promoting and anti-inflammatory signaling phenotypes.

Surprisingly, despite expressing all the pro-apoptotic components of TNFR1 Complex IIb, none of the mesothelioma cell lines examined was sensitive to SMCs, either alone or in combination with TNFα. Moreover, neither TNFα alone nor SMC alone was able to promote formation of TNFR1 Complex IIb; only cotreatment with both agents resulted in
SAHA overcomes FLIP-mediated inhibition of SMCs

N Crawford et al

formation of this potentially cell death inducing complex. However, FLIP was also recruited to this complex in TNFα and SMC cotreated cells, and using RNAi approaches, we demonstrated that this recruitment blocked caspase 8 activation and initiation of apoptosis by this complex. Thus, FLIP is a major mediator of resistance to SMCs in mesothelioma cells as determined in cocultures with physiologically relevant levels of TNFα. Furthermore, we found that both splice forms were capable of blocking apoptosis induction in response to TNFα and SMC cotreatment. Although, TNFR1 complex Iib can induce programmed necrosis (necroptosis) under certain conditions (for example, if FLIP(S) is recruited rather than FLIP(L)), we found that the mechanism of cell death induced when either FLIP splice form was downregulated in TNFα and SMC cotreated mesothelioma cells was apoptotic. These results indicate that in order for SMCs to unleash the pro-apoptotic potential of TNFα, mesothelioma cells must be cotreated with a FLIP inhibitor.

FLIP is a major antiapoptotic protein that as well as inhibiting TNFR1 complexes Ila, Iib and the ripoptosome, also blocks apoptosis induction in response to death ligands such as FasL and TRAIL and in response to various chemotherapeutic drugs in vitro and in vivo. As such, FLIP has been recognized as a potential therapeutic target for a range of cancers. However, because it lacks enzymatic activity and because there is a current lack of structural data, FLIP is a difficult therapeutic target. In addition, FLIP’s antiapoptotic activity relies on its ability to compete with procaspase 8 for binding to FADD via its death effector domains (DEDs); as the DEDs of FLIP and procaspase 8 are highly similar, any small molecule that blocks the FLIP-FADD interaction may have the unwanted effect of blocking the procaspase 8-FADD interaction. Because of these difficulties, we and others have examined a number of approaches to targeting FLIP expression. We, therefore conclude that cotreatment with SAHA (or a similar HDAC inhibitor) and a SMC could be a promising therapeutic approach for the treatment of mesothelioma that will exploit the TNFα-rich, pro-inflammatory micro-environment to induce apoptosis via TNFR1 complex Iib (Figure 8). Moreover, circulating levels of TNFα would be a candidate biomarker for sensitivity to this novel combination treatment that could be assessed routinely through non-invasive means.
Materials and Methods

Compounds. AT-IAP was supplied by Astex Pharmaceuticals (Cambridge, UK). SAHA was obtained from Selleck Chemicals (Houston, TX, USA). Z-VAD-fmk and nec-1 were purchased from Calbiochem (Gibbstown, NJ, USA). Cisplatin was obtained from Belfast City Hospital (Hospira, UK). Recombinant TNFα was purchased from Prospec (Rehovot, Israel).

Western blotting. Western blotting was carried out as previously described.41 cIAP2, XIAP and caspase 3 specific antibodies were from Cell Signaling Technology (Danvers, MA, USA). FLIP and caspase 8 antibodies were from Alexis Biochemicals (San Diego, CA, USA). PARP antibody was from eBioscience (San Diego, CA). cIAP1 was from Enzo (Exeter, UK). RIPK1 and FADD were obtained from BD Transduction Laboratories (Franklin Lakes, NJ, USA). Secondary horseradish peroxidase-conjugated antibodies (Amersham, Buckinghamshire, UK) were used for detection.

Cell lines. REN cell line was donated by Prof. Steven M. Albelda, University of Pennsylvania Medical Center, Philadelphia, USA. MM98 cell line was a kind gift from Dr Stefano Biffo from San Raffaele Scientific Institute, Milan, Italy. NCI-H28 and JU77 cells were donated by Dr Peter Szlosarek from Queen Mary University of London. NCI-H28, JU77 and MM98 cells were maintained in RPMI medium (Invitrogen, Paisley, UK) supplemented with 10% fetal bovine serum (Invitrogen). REN cells were maintained in F-12 (Hams) medium (Invitrogen) and supplemented with 10% fetal bovine serum (Invitrogen).

Generation of overexpressing cell lines. REN cell lines overexpressing FLIP(L) and FLIP(S) were generated as previously described.36

Flow cytometry. Samples were analyzed on a BD FACS Calibur flow cytometer. Cell surface TNFR1 expression was assessed following live cell staining with Phycoerythrin-conjugated TNFR1 antibody, purchased from R & D Systems (Minneapolis, MN). All experiments were carried out with an isotype control antibody. Sub G0/G1 populations were determined using propidium iodide staining (Sigma-Aldrich, Gillingham, UK) as previously described.41

siRNA transfections. Scrambled control (SCR), c-FLIP and XIAP targeting siRNAs were obtained from Dharmacon (Chicago, IL, USA). cIAP1, cIAP2, FADD and caspase 8 were purchased from Qiagen (Crawley, UK). siRNA transfections were carried out using Oligofectamine (Invitrogen) as previously described.41

Quantitative PCR. RNA was extracted using RNA STAT-60 (Tel-Test Inc., Friendswood, TX, USA) according to the manufacturer’s instructions. cDNA was synthesized using Transcriptor First Strand cDNA synthesis kit (Roche, Burgess Hill, UK) according to the manufacturer’s instructions. Quantitative PCR was carried out on LC480 using Syber green (Roche) according to the manufacturer’s instructions. Primer sequences: c-FLIP(L): F: CCT AGG AATCTGCGTGATAATC GA R:TGGGATATACCATGCATACTGAGATG, c-FLIP(S): F:ATTTCCAAGAATTT TCAGATCAGGA R:GCAGCAATCCAAAAGAGTCTCA, TNFα: F:CAGCCTCTTCTGC CCTTCGT, R:GCCAGAGGGCTGATTAGAGA, cIAP1: F: AGAAAATGCAGCAGCTGA

Figure 8  Schematic diagram summarizing the key findings. (a) Recruitment of cIAP to TNFR1 following binding by TNFα is mediated by TRADD and TRAF2 and results in RIPK1 ubiquitination, which then promotes activation of pro-survival NFκB signaling (via the LUBAC/IKK signalling complexes) and activation of the MAPK pathway (via the TAB/TAK complex). (b) In the presence of SMCs, cIAPs are polyubiquitinated and degraded by the proteasome, and RIPK1 is recruited to a second complex (Complex IIb) where it recruits FADD, FLIP and procaspase 8. SMCs can also block XIAP-mediated inhibition of caspases 3, 7 and 9. If present in sufficient amounts, FLIP will inhibit activation of caspase 8 at Complex IIb and thereby limit the activation of the downstream executioner caspases 3 and 7 with the result that the cells survive. (c) HDAC inhibitors such as SAHA efficiently target FLIP for degradation via the proteasome. Thus, when cells are cotreated with SAHA and SMC, procaspase 8 homodimers are recruited to Complex IIb, resulting in caspase 8 activation and subsequent activation of the executioner caspases and induction of apoptosis. The activation of the executioner caspases is further facilitated by SMC-mediated inhibition of XIAP.
Cell Death and Disease

Immunoprecipitation. Cells were lysed in CHAPS buffer (30 mM Tris pH 7.5, 150 mM NaCl, 1% CHAPS). One microgram of caspase-8 p18 antibody (Santa Cruz, CA, USA) was conjugated to 30 µl Protein G Dynabeads (Invitrogen). Seven-hundred and fifty microgram of protein lysate was immunoprecipitated for 6 h at 4°C. IgG isotype controls were purchased from Dako Cytomation (Cambridgeshire, UK). Immunoprecipitation experiments were analyzed by western blotting.

Caspase 3/7 activity assays. Caspase 3/7 activity was assayed using Caspase-Glo 3/7 assay system (Promega, Madison, WI).

Cell viability. Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma) assay as described previously.41

AlphaScreen. AlphaScreen assay was carried out using the anti-FLAG acceptor and GSH donor beads of the ALPHA (Amplified Luminescent Proximity Homogenous Assay) technology (Perkin Elmer, Waltham, MA, USA). FLAG-tagged FLIP(S) or FL14A mutant were expressed in HCT116 cells and cell lysates generated using CHAPS buffer. Recombinant GST-FADD was expressed in BL21 bacteria and purified. The assay was conducted in PBS in a total reaction volume of 50 µl. Two microgram of the FLAG-FLIP(S) containing lysate was incubated with 0.5 µg of GST-FADD for 45 min, following the addition of acceptor beads and donor beads, both to the final concentration of 10 µg/ml. The assay was then read on a luminometer.

Statistical analysis. Experimental results were compared using a two-tailed Students t-Test, *P<0.05, **P<0.01 and ***P<0.001.

Conflict of Interest

Prof. Fennell has worked as a consultant for Merck, who manufacture Vorinostat. Drs. Gianni Chessari and George Ward are full-time employees of Astex Pharmaceuticals who manufacture the SMAC mimetic AT-1AP used in this study. All other authors declare no conflict of interest.

Acknowledgements. NC and IS were supported by grants from the British Lung Foundation. CH was supported by CRUK.

1. Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005; 92: 587–593.
2. Choe N, Tanaka S, Xia W, Hemeway DR, Roggli VL, Kagan E. Pleural macrophage recruitment and activation in asbestos-induced pleural injury. Environ Health Perspect 1997; 105(Suppl 5): 1257–1260.
3. Li Q, Wang W, Yamada T, Matsumoto K, Sakai K, Bando Y et al. Expression patterns of inhibitor of apoptosis protein family members in malignant mesothelioma. Int J Cancer 2012; 24: 449–463.
4. Krueger A, Schmitz I, Baumann J, Kritsch M, Hiltot-Jones C et al. Mutational analyses of SMAC, a mitochondrial protein that promotes cell death, inducing signaling complex. J Biol Chem 2001; 276: 20833–20840.
5. Ueffing N, Keil E, Freund C, Kuhne R, Schulze-Osthoff K, Schmitz I. Mutational analyses of c-FLIPR, the only murine short FLIP isoform, reveal requirements for DISC recruitment. Cell Death Differ 2007; 14: 1371–1381.
36. Logan AE, Wilson TR, Fenning C, Cummins R, Kay E, Johnston PG et al. In vitro and in vivo characterisation of a novel c-FLIP-targeted antisense phosphorothioate oligonucleotide. Apoptosis 2010; 15: 1435–1443.

37. Panner A, James CD, Berger MS, Pieper RO. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 2005; 25: 8809–8823.

38. Wilson TR, McLaughlin KM, McEwan M, Sakai H, Rogers KM, Redmond KM et al. c-FLIP: a key regulator of colorectal cancer cell death. Cancer Res 2007; 67: 5754–5762.

39. Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L et al. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 2006; 25: 838–848.

Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)